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Background: Aerobic glycolysis, namely the Warburg effect, is the main hallmark of cancer cells. Mitochondrial
respiratory dysfunction has been proposed to be one of the major causes for such glycolytic shift. This hypothesis
has been revisited as tumors appear to undergo waves of gene regulation during progression, some of which rely
on functional mitochondria. In this framework, the role of mitochondrial complex I is still debated, in particular with
respect to the effect of mitochondrial DNA mutations in cancer metabolism. The aim of this work is to provide the
proof of concept that functional complex I is necessary to sustain tumor progression.
Methods: Complex I-null osteosarcoma cells were complemented with allotopically expressed complex I subunit 1
(MT-ND1). Complex I re-assembly and function recovery, also in terms of NADH consumption, were assessed.
Clones were tested for their ability to grow in soft agar and to generate tumor masses in nude mice. Hypoxia levels
were evaluated via pimonidazole staining and hypoxia-inducible factor-1α (HIF-1α) immunoblotting and
histochemical staining. 454-pyrosequencing was implemented to obtain global transcriptomic profiling of allotopic
and non-allotopic xenografts.
Results: Complementation of a truncative mutation in the gene encoding MT-ND1, showed that a functional
enzyme was required to perform the glycolytic shift during the hypoxia response and to induce a Warburg profile
in vitro and in vivo, fostering cancer progression. Such trigger was mediated by HIF-1α, whose stabilization was
regulated after recovery of the balance between α-ketoglutarate and succinate due to a recuperation of NADH
consumption that followed complex I rescue.
Conclusion: Respiratory complex I is essential for the induction of Warburg effect and adaptation to hypoxia of
cancer cells, allowing them to sustain tumor growth. Differently from other mitochondrial tumor suppressor genes,
therefore, a complex I severe mutation such as the one here reported may confer anti-tumorigenic properties,
highlighting the prognostic values of such genetic markers in cancer.
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Aerobic glycolysis is one of the main hallmarks of cancer
cells. The seminal observation by Otto Warburg at the be-
ginning of last century [1,2] has fostered compelling efforts
in elucidating the profound metabolic changes that
transformed cells undergo from initial tumor to the spread
of metastases, which to date remain largely obscure. It is
still unclear why highly proliferative and invasive cancer
cells settle for an energetically less efficient aerobic glycoly-
sis, rather than oxidative phosphorylation (OXPHOS),
which generates far more ATP from a single glucose mol-
ecule. The shift toward glycolysis has been ascribed to four
potential causes, namely (i) a mitochondrial dysfunction,
which forces cells to rely on glycolysis, (ii) an upregulation
of glycolytic genes driven by the activation of oncogenes,
(iii) the triggering of a strong hypoxic response that
turns down oxygen-dependent respiration and (iv)
the redirection of glucose catabolism towards macro-
molecular biosynthesis [3,4].
The classical Warburg hypothesis has recently been
revisited, as tumors with active mitochondrial metabolism
have been identified, indicating that aerobic glycolysis does
not necessarily involve a decrease in mitochondrial function
[5]. It is likely that glycolytic and oxidative metabolisms
interchange in a wave pattern during the proliferation and
transformation of cancer cells, constantly subjected to
selective pressures in terms of nutrients and oxygen
availability, determined by the ever-changing tumor micro-
environment [6]. In this context, mitochondria might repre-
sent the main hub for the wave-like regulation of cancer
metabolism [7]. In fact, they host a number of essential
metabolic processes, such as the oxygen-dependent ATP
production, redox regulation and biosynthetic reactions [8].
Moreover, mitochondria are involved in the regulation of
hypoxic adaptation [9], a process that must be triggered in
any solid neoplasia to overcome the initial steps of tumori-
genesis and is controlled by hypoxia-inducible factor 1α
(HIF-1α) [10].
During O2 deprivation, HIF-1α stabilization and acti-
vation is needed for cells to respond to hypoxia,
upregulating the expression of pivotal glycolytic genes
[11]. Therefore, in this condition, HIF-1α increases
glycolysis and suppresses the tricarboxylic acids (TCA)
cycle and, ultimately, mitochondrial respiration [12,13].
HIF-1α stabilization is tightly controlled by prolyl-
hydroxylases (PHDs), enzymes whose HIF-1α-degrading
activity is allosterically regulated by α-ketoglutarate
(α-KG) and succinate (SA), two key metabolites of the
TCA cycle, which feeds reducing equivalents to the re-
spiratory chain for ATP production. In this frame, we
have recently shown that a dysfunction in complex I
(CI), caused by the severe m.3571insC/MT-ND1 mito-
chondrial DNA (mtDNA) mutation, strongly contributes
to HIF-1α destabilization and lack of hypoxia adaptation,which eventually leads to an antitumorigenic effect
[14,15]. Complex I is the largest and least understood
component of the respiratory chain, which catalyzes the
transfer of electrons from NADH to flavin mononucleo-
tide and then to ubiquinone [16]. The holoenzyme
function is necessary for ATP production and for the
maintenance of cellular redox state, such as NAD+/NADH
ratio and reactive oxygen species (ROS) levels [17]. Com-
plex I dysfunction, specifically that induced by the occur-
rence of mutations in respiratory genes encoded within
the multicopy mtDNA, has generally been described as
pro-tumorigenic [18,19]. An open debate scans the evi-
dence that mtDNA mutations, according to their overall
effect on the respiratory chain and, indirectly, on other
oxidative metabolism pathways, may not behave uni-
vocally as pro-tumorigenic and pro-metastatic events
[15,20]. Mutations in CI genes encoded within the
mtDNA, in fact, have been shown both to foster and in-
hibit the replication of tumors in which they occur, a two-
sided effect that depends on the percentage of mutant
mtDNA copies (heteroplasmy) and on the capacity of the
mutation to disassemble CI [21]. Therefore, it is likely that
CI may no longer be looked upon as an enzyme that
merely contributes to mitochondrial function. Neverthe-
less, although its role in determining the fate of cancer
cells upon deregulation of their metabolic switch during
tumor progression is considered increasingly crucial, it re-
mains ambiguous. Furthermore, the molecular mecha-
nisms through which CI may regulate metabolic
adaptation in tumorigenesis still remain practically
uninvestigated.
In the attempt to assign a role to CI within the
Warburg effect, we have demonstrated that this mito-
chondrial enzyme is required in order to perform the
metabolic switch towards glycolysis during the hypoxia




In this study, 143B osteosarcoma-derived cybrids harbor-
ing the homoplasmic m.3571insC mutation in MT-ND1
[HGCN:7455], their counterpart OS-93ND1, allotopically
complemented with wild-type MT-ND1 and their wild-
type mtDNA counterpart (CC) were used. Mock cells
transfected with empty vector are indicated as OS-93.
Cybrids were obtained and cultured as previously de-
scribed [15].
Nucleic acid extraction
DNA from snap-frozen xenografts and cultured cells
(7 × 105) was extracted with GenElute™ Mammalian
Genomic DNA Miniprep Kit (Sigma-Aldrich, Milan,
Italy). RNeasy Plus Mini kit (Qiagen, Milan, Italy) was
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lines RNA was obtained using TRIzol reagent (Invitrogen,
Milan, Italy) and following manufacturer’s instructions.
MT-ND1 allotopic construct
Wild-type MT-ND1 was cloned from cDNA of TPC1
cells derived from a papillary thyroid carcinoma [22] and
inserted into a p3XFLAG-CMV™-14 expression vector
(Sigma-Aldrich, Milan, Italy). The MT-ND1 sequence
was identical to the mtDNA revised Cambridge Refer-
ence Sequence (rCRS) [GenBank:NC_012920.1]. FLAG
epitope was excluded from the transgene frame in order
not to affect protein folding. COX10 [GenBank:U09466]
30- and 50-UTR were cloned according to Bonnet et al.
[23]. The 50-UTR from nuclear-encoded mitochondrial
protein COX10 was cloned upstream of nND1
for mRNA targeting to the mitochondria outer mem-
brane, along with mitochondrial targeting sequence (N-
terminal MTS). The 30-UTR from COX10 was inserted
downstream of nND1 in order to ensure mRNA stability.
Site-directed in vitro mutagenesis was performed with
the QuikChange Lightning Multi Site-Directed Muta-
genesis Kit (Strategene, Agilent Technologies, Santa
Clara, CA, USA) according to the manufacturer’s
instructions. Oligonucleotides designed for this purpose
are available on request.
Cell transfection, selection and assessment of allotopic
MT-ND1 expression
Cells were transfected with p3XFLAG-CMV™-14 empty
vector and with the nND1 allotopic construct by using
Lipofectamine 2000 transfection reagent (Invitrogen,
Milan, Italy) following the manufacturer’s protocol. Stable
clones were obtained by selection with 400 μg/mL G418
(Invitrogen, Milan, Italy) and the antibiotic resistant
clones were double-selected by growing them in DMEM
without glucose supplemented with 5 mM galactose,
5 mM Na-pyruvate and 10% FBS, in order to eliminate
false positive clones. The expression of allotopic ND1 was
assessed by quantitative real-time PCR (qRT-PCR). Total
RNA was extracted from OS-93 and OS-93ND1 clones and
1 μg was used for retrotranscription with Transcriptor First
Strand cDNA Synthesis Kit (Roche Diagnostics, Monza,
Italy), by using random hexameric primers. Primer and
TaqManW probes sequences were designed using Primer3
software [24] and the presence of 30 intra-/inter-primer
similarity was ruled out using IDT OligoAnalyzer tool [25].
Sequences are available upon request. Allotopic nND1 PCR
product spanned the region between the COX10 MTS and
50-nND1, in order to exclude any endogenous transcript,
and the normalization was performed on pCMV levels,
which is present in plasmid DNA but not translated, in
order to exclude plasmid DNA contamination. Human
ACTB gene[GenBank:M28424] was used as reference gene.The PCR reaction was performed with LightCyclerW 480
Probes Master and run in LightCyclerW480 Real-Time PCR
System (Roche Diagnostics, Monza, Italy), using the follow-
ing conditions: 95°C, 5 minutes; 45 cycles of 95°C, 15 sec,
and 60°C, 45 sec. Absolute quantification was performed
using a standard curve prepared by serial dilutions of puri-
fied p3XFLAG-CMV™-14 containing the allotopic construct.mtDNA sequencing and low heteroplasmy detection
Whole mtDNA resequencing was performed as previ-
ously described [26] in order to verify that xenografts
had not accumulated mutations apart from the
m.3571insC. Mutant load of m.3571insC was determined
using fluorescent PCR (F-PCR) and denaturing high per-
formance liquid chromatography (DHPLC) according to
previously optimized protocols for mutations in difficult
sequence contexts such as homopolymers [27]. Each
analysis was performed in triplicate.SDS-PAGE
Mitochondrial enriched fraction was obtained by the
subcellular fractionation in the presence of digitonine
(50 μg/mL) [28]. Total lysates were prepared from
30 mg of xenografts as previously described [15].
Mitochondrial proteins (40 μg) or total xenograft and
cell lysates (80 μg) were separated by 10% SDS-PAGE
and transferred onto nitrocellulose membrane as previ-
ously reported [15].Western blot
Nitrocellulose membranes were incubated with anti-
bodies against voltage-dependent anion channel (VDAC)
(1:1000, BioVision, Mountain View, CA, USA), ND1
(1:1000, a gift from A. Lombes, Unite de Recherche
INSERM 153, Hospital de la Salpetriere, Paris, France),
HIF-1α (1:1000, Bethyl Laboratories, Montgomery, TX,
USA), LDHA (1:1000, Sigma-Aldrich, Milan, Italy). Sec-
ondary antibodies used were peroxidase-conjugated anti-
mouse or anti-rabbit (1:2000, Jackson ImmunoResearch,
Suffolk, England). Chemiluminescence signals were
obtained with Kodak molecular imaging apparatus
(Kodak, Rochester, NY, USA). Coomassie staining was
used as the loading control.Complex I In-Gel-Activity (CI-IGA) assay
Mitochondrial enriched fractions (for sample prepar-
ation see section SDS-PAGE) were solubilized with
n-dodecyl-maltoside (2.5 g/g protein) as previously
reported [29]. Proteins (100 μg) were separated by 4 to 13%
Blue Native gradient gel (BN-PAGE) and CI-IGA was
detected as previously described [30].
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Aliquotes of 1.5 × 106 cells were washed and resuspended
in 1 mL of ice-cold PBS and extracted for NADH and
NAD+ determination. For NADH analysis, cell suspension
was treated with 0.5 M potassium hydroxide containing
50% (v/v) ethanol and 35% (w/v) cesium chloride, immedi-
ately cooled on ice, centrifuged at 4°C to remove insoluble
material and the supernatant (100 μL) was injected on C18
column. For NAD+ determination, cell suspension was
treated with 1 M perchloric acid, immediately cooled on
ice, and centrifuged at 4°C to remove insoluble material.
Perchloric acid was neutralized with potassium hydroxide
and centrifuged immediately before injection. The super-
natant was injected (100 μL) on C18 column. The pyridine
nucleotides were extracted and detected as described [31]
on a Kinetex reversed phase C18 column (250 × 4.6 mm,
5 μm; Phenomenex, Torrance, CA, USA), with a two-pump
Waters 510 system equipped with a variable volume in-
jector. Absorbance at 260 nm for NAD+ and at 340 nm for
NADH was monitored by a photodiode array detector
(Waters 996). NADH and NAD+ peaks were identified by
comparison of their retention times with those of standards
and confirmed by co-elution with standards. The quan-
tification was obtained from peak area measurement
compared to standard curves.
ATP synthesis measurement
The rate of mitochondrial ATP synthesis driven by CI
and CII was performed in aliquots of digitonin-
permeabilized cells and normalized on citrate synthase
(CS) activity as previously described [32]. Briefly, ali-
quots (0.1 to 0.2 mg protein) were incubated with 5 mM
malate plus 5 mM pyruvate (CI substrates) or with
10 mM succinate (CII substrate) plus 2 μg/mL rotenone.
The reaction was started by addition of 0.2 mM ADP in
the presence of luciferine/luciferase, and chemilumines-
cence was evaluated as a function of time with a
luminometer. After addition of 10 μM oligomycin, the
chemiluminescence signal was calibrated with an in-
ternal ATP standard.
Oxygen consumption rate (OCR)
OCR in adherent cells was measured with an XF24
Extracellular Flux Analyzer (Seahorse Bioscience, Biller-
ica MA, USA). Cells were seeded in XF24 cell culture
microplates at 3 × 104 cells/well in 200 μL of DMEM
containing 4.5 g/L glucose and incubated at 37°C in 5%
CO2 for 24 h. Assays were performed as previously
reported [32]. Data are expressed as pmoles of O2 per
minute per 3 × 104 cells.
Mitochondrial membrane potential determination
Cells (3 × 105) were seeded onto 24 mm-diameter round
glass coverslips and grown for 2 days. Mitochondrialmembrane potential (ΔΨm) was measured by the accumu-
lation of tetramethylrhodamine methyl esther (TMRM) as
previously reported [30]. Data were acquired and analyzed
using MetaFluor software (Universal Imaging Corp.,
Downington, PA, USA). Clusters of several mitochondria
were identified as regions of interest, and fields not con-
taining cells were taken as background. Sequential digital
images and fluorescence intensity were acquired every
minute. Fluorescence values were obtained by subtracting
background values from those of corresponding mito-
chondrial areas of interest, for each time point, and
expressed as percentage of T0 (100%).
Soft agar
Anchorage-independent cell growth was determined in
0.33% agarose with a 0.5% agarose underlayer. Cell
suspensions (2 × 104 cells) were plated in semisolid medium,
in absence or presence of 1 μM dimethyloxallylglycine
(DMOG). Colonies were counted after 7 days at a magnifi-
cation of 10× with an inverted microscope (Nikon Diaphot,
Nikon Instruments, Florence, Italy). Plate pictures and
magnifications were obtained with a Kodak molecular im-
aging apparatus (Kodak, Rochester, NY, USA). Effects of
DMOG on HIF-1α stabilization were validated by western
blotting (Additional file 1: Figure S1). The index of colony
forming ability was calculated as the ratio between un-
treated OS-93ND1 and OS-93 cells and then used for
normalization of DMOG-treated cells. The t-test was used
for statistical comparison.
In vivo tumor growth analysis
Cells (3 × 106) were suspended in 0.2 mL sterile PBS
and injected subcutaneously in 4 to 7 week-old athymic
Crl:CD-1-Foxn1nu/nu mice (referred to as nude mice,
purchased from Charles River, Lecco, Italy). Experiments
were authorized by the institutional review board of the
University of Bologna and performed according to
Italian and European guidelines. Individually tagged
virgin female mice (10 per experimental group) were
used. Tumor growth was assessed with a caliper; volume
was calculated as:
Π √ a  bð Þ 3=6
where a = maximal tumor diameter, and b = tumor diam-
eter perpendicular to a.
Electron microscopy
Xenograft biopsies were immediately collected and
processed as previously described [15]. Samples were ob-
served with a JEM-1011 Transmission Electron Micro-
scope (Jeol Ltd, Milan, Italy).
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Ultradeep pyrosequencing was performed using 454 GS
FLX Titanium platform (Roche Diagnostics, Monza,
Italy). RNA quality was assessed by a 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). Total
RNA from each sample (5 to 8 μg) was used for poly(A)
mRNA selection, using Oligotex mRNA kit (Qiagen,
Milan, Italy). The poly(A)-enriched RNA samples were
reverse-transcribed into cDNA using random-sequence
primers. cDNA libraries preparation and subsequent
pyrosequencing (applying 200-nucleotide cycles) were
carried out according to the manufacturer’s instructions.
RNA-Seq data analysis
RNA-seq reads obtained (Additional file 2: Table S1) were
tested for sequence quality by FastQC [33] (Additional
file 3: Figure S2) and those ≥100 bp were mapped onto the
hg18/NCBI36-annotated human genome, using the Next
Generation Sequencing. TRanscriptome profile Explorer
(NGS-Trex) platform [34]. Multiple mappings were allowed
to avoid too large a cutoff derived from paralogous genes
(Additional file 4; Methods). Genes were considered
expressed if at least one read was mapped. Raw digital
expression read count per gene (considering all the mapped
mRNA isoforms together) was used for the differential
expression analysis with the edgeR [35] package of
Bioconductor [36] (Additional file 4; Methods). Only genes
with at least one read in all the four samples studied were
considered in the statistical analysis using Fisher’s exact test.
A P-value ≤0.05 was used as the threshold to consider a
gene as differentially expressed (DE). The Bioconductor
goseq [37] package was used to associate all DE genes to
Gene Ontology (GO) categories and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways (Additional file 4;
Methods), while the GeneMania server [38] was used to
carry out gene network analyses by searching among
several interaction databases, related bibliographic refer-
ences and for GO categories enrichment within only
overexpressed genes found in each group. The HIF-1α
pathway reconstruction was manually curated [39-44] from
interaction databases (BioGRID, HPRD, Pathway Com-
mons, GEO dataset), with GeneMania and from NCBI
Interaction and GeneRIF sections of the HIF-1A gene entry
[45]. Representation of upregulated and downregulated
genes in the heatmaps was prepared using the limma pack-
age of R [46], applying a hierarchical clustering onto log2
normalized digital gene expression values (Additional file 4;
Methods). Validation of RNA-Seq data was performed with
qRT-PCR as indicated in Additional file 4; Methods.
Immunohistochemical analysis
Immunohistochemical (IHC) analysis with antibodies
against NDUFB8 subunit of CI (Invitrogen, Milan, Italy)
and HIF-1α (Upstate Biotech, Billerica, MA, USA) wasperformed as previously reported [47]. The semi-
quantitative analysis of the stained sections was done by
light-microscopy at 100× magnification. The evaluation
of cytoplasmic NDUFB8 immunostaining was performed
according to the percentage of positive cells (range 0 to
4) and to the staining intensity (range 0 to 3) using a
modified immunoreactivity score (IRS) [48,49]. The final
staining evaluation for each sample was obtained by
combining the two values (range 0 to 12). The population
of cells with a positive HIF-1α nuclear immunostaining was
quantified using a computerized, morphometric, inter-
active, digital image analysis as previously described [50].
The labeling index was expressed as the percentage of the
labeled nuclear area over the total nuclear area for tumor
cells in the section.
Pimonidazole staining
Animals were injected intraperitoneally with 60 mg/kg
pimonidazole (Hypoxyprobe-1 Plus Kit, HPI, Burlington,
MA, USA) 3 h prior to sacrifice. Xenografts were treated
and fluorescence visualized as previously reported [15].
α-KG and SA measurements
Measurements of metabolites α-KG and SA were carried
out in ex vivo cell lines derived from OST-93 and
OST-93ND1 essentially as previously described [15]. The
t-test was used for statistical comparison.
Statistical analyses
Analysis of variance (ANOVA) was used for all statistical
analyses unless otherwise indicated.
Results
Allotopic MT-ND1 expression corrects CI-dependent
mitochondrial energetic dysfunction
In order to recover CI function, we took advantage of
the previously characterized osteosarcoma cell models
(OS-93) bearing the quasi-homoplasmic disruptive
m.3571insC mutation in the MT-ND1 gene, which en-
codes the NADH dehydrogenase subunit 1 (ND1) of CI
[14,15] (Additional file 5: Figure S3A). The mutation
was complemented by recoding MT-ND1 for cytosolic
translation (nND1) using in vitro site-directed mutagen-
esis (Additional file 5: Figure S3B). A eukaryotic expres-
sion construct was designed with the aim to facilitate
nND1 mRNA targeting to the outer mitochondrial
membrane [23] (Additional file 5: Figure S3C). ND1-null
OS-93 cells were then transfected with the allotopic
construct to generate OS-93ND1 clones, in which
nND1 mRNA expression was confirmed by qRT-PCR
(Additional file 5: Figure S3D). Western blot analysis on
enriched mitochondrial fractions showed that ND1 was
present exclusively in OS-93ND1 allotopic clones
(Figure 1A), indicating that the protein was correctly
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addressed the issue of genetic revertants by measuring
the precise load of mutant mtDNA by F-PCR (Figure 1B)
and DHPLC (Additional file 6: Figure S4). Genetic rever-
tants were not carried along in subsequent analyses.
Moreover, by sequencing the whole MT-ND1 gene,
clones were repeatedly controlled so that no additional
mutations had accumulated that could complement theFigure 1 Expression and functional effects of allotopic nND1. (A) West
representative clones. Voltage-dependent anion channel (VDAC) was used
(B) m.3571insC mutation load evaluation by fluorescent (F)-PCR. Wild-type
homopolymeric stretch, where 7C corresponds to the C insertion. (C) Com
is indicated with an arrow. One representative experiment of four is shown
lysates. Data (mean ± SD) are expressed as pmoles of NADH and normalize
consumption rate (OCR). Measurements were performed upon injection of
phenylhydrazone (FCCP) (F), 1 μM rotenone (R) and 1 μM antimycin A (AA)
that of OS-93ND1 cells. Data (mean ± standard error of the mean (SEM)) are
(G) Mitochondrial ATP synthesis driven by pyruvate/malate and succinate, C
#undetectable value; **OS-93 vs CC, P <0.01; **OS-93ND1 vs OS-93, P <0.01; *
evaluation in CC, OS-93 and OS-93ND1 cells. Arrows indicate the addition o
Fluorescence readings following the addition of oligomycin and preceding
all time points between OS-93 and both CC and OS-93ND1 cells.m.3571insC, for example, via recovery of the open read-
ing frame. No difference in growth rate was found in
glucose medium between CI-deficient and CI-competent
cell clones (Additional file 7: Figure S5), indicating their
basal metabolism to be mainly glycolytic, as it occurs
generally when cells grow in vitro in presence of nutri-
ents and oxygen. In order to verify whether the nND1
subunit was able to restore functional CI, theern blot analysis for ND1 in control (CC), OS-93 and OS-93ND1
as a loading control. One representative experiment of three is shown.
and mutant fragments are distinguished based on the length of the
plex I in-gel activity (CI-IGA) assay in isolated mitochondria. CI-IGA band
. (D-E) NAD+/NADH ratio and NADH levels were measured in cell
d for protein content (n = 3; *P <0.05; **P <0.01). (F) Oxygen
1 μM oligomycin (O), 0.1 μM trifluorocarbonylcyanide
. The inset shows the OCR control cell line (CC) profile, analogous to
expressed as pmoles of O2 per minute per 3 × 10
4 cells (n = 3).
I and CII substrates, respectively. CS, citrate synthase. (n = 4;
CC vs OS-93ND1, P <0.05). (H) Mitochondrial membrane potential
f 6 μM oligomycin (O) and 4 μM FCCP (F). Data are mean ± SEM (n = 6).
that of FCCP revealed a statistically significant difference (P <0.05) for
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were explored. CI-IGA analysis showed a band corre-
sponding to fully assembled and functional CI in both
wild-type mtDNA control (CC) and in OS-93ND1 cells,
but not in OS-93 (Figure 1C), indicating a recovery of
CI activity. This finding was confirmed by measuring the
NAD+/NADH ratio, which was significantly recuperated
by about 50% in OS-93ND1 compared to OS-93 cells
(Figure 1D), likely due to recuperated consumption of
NADH in the allotopic clone, albeit not as much as in
control cells (Figure 1E). The basal respiration of OS-
93ND1 clones was higher than in OS-93 and it was inhibited
by oligomycin, indicating at least a partial rescue of
phosphorylation capacity (Figure 1F). Furthermore, respir-
ation was stimulated by addition of the uncoupler
trifluorocarbonylcyanide phenylhydrazone (FCCP) and
largely inhibited by rotenone and antimycin A (AA),
confirming the rescue of CI function (Figure 1F). This
finding was strengthened by the fact that OS-93ND1 cells
partially but significantly recuperated CI-driven ATP syn-
thesis compared to OS-93, as evaluated in digitonin-
permeabilized cells in the presence of specific substrates
(Figure 1G). No difference in CII-driven ATP synthesis was
detected between allotopic and ND1-null cells, suggesting
no alteration of the remaining spans of oxidative phosphor-
ylation (Figure 1G). Moreover, similarly to CC, mitochon-
drial membrane potential (ΔΨm) was maintained in
allotopic cells after the addition of the ATP-synthase inhibi-
tor oligomycin, whereas OS-93 cells rapidly depolarized
(Figure 1H). Taken together, these results demonstrate that
ND1 allotopic expression permitted recovery of a func-
tional CI and rescued cellular bioenergetics competence.
Complex I-competent allotopic clones recover
tumorigenic potential
To address the question of whether CI function is re-
quired for cancer cell growth, CC, OS-93 and OS-93ND1
were tested for their capacity to grow in an anchorage-
independent manner. Allotopically complemented cells
formed larger and significantly more numerous colonies
than their mock clones (Figure 2A-B). Cells were injected
in nude mice to determine their tumorigenic potential
in vivo. Similar to controls, OS-93ND1-derived tumors
(OST-93ND1) grew significantly larger than those derived
from OS-93 cells (OST-93) (Figure 2C), demonstrating that
the recovery of CI function in vivo (Figure 2D) is required
for tumor growth. We have previously demonstrated that
in the presence of a quasi-homoplasmic m.3571insC muta-
tion, mitochondrial morphology is heavily deranged [15]. In
fact, electron micrographs of OST-93 tumors showed large
mitochondria with clear matrix and almost total loss of
cristae (Figure 2E). On the other hand, OST-93ND1 and CC
tumors presented with a population of mitochondria
mostly with darker matrix and normal cristae (Figure 2E),indicating that the recovery of CI function was strictly asso-
ciated with a recuperation of a normal mitochondrial
morphology. These findings confirm the beneficial effects
of allotopic ND1 expression on mitochondria in vivo. In
order to rule out that such recovery might be due to a
genetic reversion occurring during xenograft growth, we
resequenced the mtDNA derived from the tumors and no
other mutations apart from the m.3571insC were detected.
Occurrence of revertant genotypes was also excluded by F-
PCR (Figure 2F) and DHPLC analysis (Additional file 8:
Figure S6). Overall, these data clearly indicate that CI
function is required to sustain tumor growth in vivo.
We next addressed the involvement of ROS, since they
have been shown to positively contribute to tumor
growth and metastasis [18,51]. Hydrogen peroxide and
superoxide levels were measured in the absence and in
presence of AA (Additional file 4; Methods), an inhibitor
of complex III (CIII) and the main superoxide inducer
[17]. We previously reported that CI-ablated cells may
be expected to produce fewer radicals, due to lack of
one of the two ROS production sites [14,15], a trend we
also observed here between CC and both OS-93 and
allotopic OS-93ND1 (Additional file 9: Figure S7A-B),
albeit not significant. Further, upon AA treatment, a
significant increase in ROS levels was observed only in
CC, whereas no increase was shown to occur in OS-93
and OS-93ND1 cells. These findings suggest that the
severe CI mutation may not permit the normal electron
flow through the complex and the rest of the respiratory
chain, failing to ensure a minimal amount of electrons
required for production of radicals, even in the presence
of inhibited CIII. In allotopic cells, we failed to detect a
rescue of ROS levels, indicating that the amount of fully
re-assembled CI was lower than in CC cells, finally
allowing us to rule out a major ROS contribution in
determining the different tumorigenic potential of
allotopic compared to CI-deficient cells.
Global transcriptomic profiling reveals a HIF-
1α-regulated Warburg phenotype in allotopic tumors
With the aim of dissecting the molecular pathways de-
termining tumor growth or arrest in dependence of CI
recovery, we next conducted a global transcriptomic
profiling on OST-93 and OST-93ND1 xenografts. We
found 521 DE genes, out of which 226 upregulated in
OST-93 and 296 in OST-93ND1 samples (Figure 3A and
Additional file 2: Table S1), with fold changes ranging
between 2.0 and 13.8. The most significant GO categories
among OST-93ND1 upregulated genes included the acti-
vation of the translational apparatus (Additional file 10:
Table S2).
We have previously demonstrated that CI-deficient
tumors are unable to respond to hypoxia via the
destabilization of transcription factor HIF-1α [14,15]. In
Figure 2 Complex I (CI) function is required for recovery of tumorigenic potential in vitro and in vivo. (A) Representative images of
anchorage-independent colony growth in soft agar of control (CC), OS-93 and OS-93ND1 cell lines. (B) Colony count on soft agar plate after
7 days; data are mean ± SD (n = 3, *P <0.05). (C) Tumor growth induced upon injection of CC, OS-93 and OS-93ND1 cell lines in nude mice. Data
are mean ± standard error of the mean (SEM) (n = 3, 5 to 10 animals inoculated in each experiment; *P <0.05; *CC and OS-93ND1 versus OS-93).
(D) CI-in gel activity (IGA) assay in tumor homogenates from CC, OST-93 and OST-93ND1 tumors. One representative experiment of three is
shown. (E) Representative electron micrographs of CC, OST-93 and OST-93ND1 tumors. Asterisks indicate diverse mitochondrial morphology.
(F) Fluorescent-PCR analysis of the m.3571insC in OS-93 and OS-93ND1 cell lines and xenografts (OST). All xenografts maintained the same
m.3571insC mutant load as their corresponding cell lines (>90%).
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targets, we specifically looked at such pathways within
the set of DE genes. Interestingly, 21 out of 521 genes
were downstream targets of HIF-1α (Figure 3B), most of
which were known to be overexpressed during the hyp-
oxia response. Remarkably, HIF-1α-responsive NDRG1,
LGALS3 and IGFBP3, overexpressed in OST-93ND1 tu-
mors, were among the top-ranked DE genes detected
here, with a false discovery rate (FDR) <5% (Additional
file 2: Table S1). In agreement with data on known HIF-
1α-repressed gene targets, a significant under-expression
of MCM10, BRCA1 and TPM1 was found in OST-93ND1
tumors, suggesting an overall activation of the HIF-1α-
regulated pathway occurring exclusively in allotopic
xenografts (Figure 3B). Among HIF-1α-responsive genes,
a cluster of four belonging to the glycolytic pathway
(PFKP, GAPDH, PGK1 and LDHA) and two encoding
glucose transporters (SLC2A1, SLC2A3) were significantlyoverexpressed in OST-93ND1 tumors (Figure 3B-C). No
other significant differential expression was evident from
the transcriptomic data analysis regarding genes involved in
cellular metabolism, indicating that glycolysis may be
prevalently responsible for the higher growth ability of CI-
competent cancer cells, suggesting the existence of a
Warburg transcriptional profile in such tumors.
Transcriptomic data were confirmed and validated
by qRT-PCR (Figure 3D), which highly correlated
(R2 = 0.91) with the RNA-Seq data (Additional file 11:
Figure S8).
HIF-1α stabilization occurs upon CI recovery and
decreased α-KG/SA ratio
To assess whether restoring CI via nND1 expression af-
fected HIF-1α stabilization, IHC analysis was performed
on OST-93 and OST-93ND1 xenografts. Positive staining
of both the NDUFB8 CI subunit and HIF-1α was found
Figure 3 Transcriptional profile of OST-93 and OST-93ND1 xenografts. (A) Heatmap displaying expression levels of the 521 differentially
expressed (DE) genes in the samples analyzed. Dark red = upregulated genes; cyan = downregulated genes. (B) The transcriptional profile of the
Warburg phenotype. Heatmap showing gene expression profile of 21 DE genes from the hypoxia inducible factor-1α (HIF-1α) activation pathway.
Genes are ordered by decreasing log2 fold change. Glucose transporters and glycolytic genes are marked in red. (C) Glucose uptake and
glycolytic reactions. Genes overexpressed in OST-93ND1 xenografts are labeled in red. Red circles represent glucose molecules. (D) Quantitative
real-time PCR validation performed on biological replicates of OST-93 (n = 2) and OST-93ND1 (n = 7) for 9/21 HIF-1α-responsive genes found DE in
RNA-Seq (*P <0.05).
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http://www.cancerandmetabolism.com/content/1/1/11only in OST-93ND1 tumors (Figure 4A panels a-d). Both
OST-93 and OST-93ND1 masses positively stained with
hypoxic marker pimonidazole, indicating that HIF-1α
was not stabilized in OST-93 tumors despite the low-
oxygen tension microenvironment in vivo (Figure 4A
panels e-f). The strong association between CI and HIF-1α
stabilization was furthermore evident from the high cor-
relation (R2 = 0.898) of the NDUFB8 and HIF-1α IHCFigure 4 (See legend on next page.)staining (Figure 4B). Moreover, the protein expression
levels of HIF-1α and its downstream target LDHA, were
increased only in OST-93ND1 xenografts, demonstrating
that HIF-1α was only functional in CI-competent tumors
(Figure 4C). Since HIF-1α turnover is known to be af-
fected by the α-KG/SA ratio, we investigated the levels of
these two tricarboxylic acid (TCA) cycle metabolites in
OST-93- and OST-93ND1-derived cells. The α-KG/SA
(See figure on previous page.)
Figure 4 Complex I (CI) rescue correlates with decrease in α-ketoglutarate (α-KG)/ succinate (SA) ratio and recovery of hypoxia
inducible factor-1α (HIF-1α) stabilization. (A) Representative immunohistochemical (IHC) analysis of CI (NDUFB8) and HIF-1α in OST-93 and
OST-93ND1 xenografts. Positive NDUFB8 (b) and HIF-1α staining (d) is observed in OST-93ND1 but not in OST-93 xenografts (a, c); magnification
100×. Pimonidazole staining of representative OST-93 and OST-93ND1 xenografts (e, f); magnification 63×. (B) Correlation between NDUFB8 and
HIF-1α IHC staining scores. X-axis represents NDUFB8 staining scores obtained considering the percentage of positive cells and staining intensity.
Y-axis represents the percentage of HIF-1α-positive nuclei. (C) Western blot analysis of HIF-1α and lactate dehydrogenase A (LDHA) protein levels
in OST-93 and OST-93ND1 tumors. Coomassie staining was used as loading control (input). (D) The ratio of α-KG and SA levels was calculated by
measurements for each metabolite in OST-93- and OST-93ND1-derived cell lines. Data are mean ± SD (n = 3, *P <0.05). (E) Scheme of the metabolic
changes in the absence/recovery of functional CI in cancer cells. Non-functional CI leading to an increase of the α-KG/SA ratio (left panel), which
may foster activity of prolyl-hydroxylases (PHDs) with subsequent HIF-1α degradation even at low oxygen. Inactivation of HIF-1α leads to the
downregulation of glycolysis needed to compensate for the defective mitochondrial respiration. This scenario may not allow the metabolic
adaptation of tumor cells, possibly inducing a short-circuited mitochondrial compensatory proliferation. Due to a recuperated NADH
consumption, CI rescue restores the α-KG/SA balance (right panel), hence not preventing HIF-1α stabilization. HIF-1α may therefore translocate
into the nucleus with HIF-1β and activate transcription of target genes (red ovals and rectangles), among which those contributing to increase
the glycolytic flux, hence conferring a Warburg phenotype and allowing tumor adaptation and growth. Red elements indicate activation
or overexpression.
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OST-93ND1 (Figure 4D), clearly indicating that CI func-
tion influenced the balance of these TCA cycle metabo-
lites and in turn, permitted HIF-1α stabilization. Last, we
attempted to verify whether HIF-1α was responsible for
the augmented tumorigenic potential of allotopic com-
pared to CI-deficient cells. To this aim, we used the po-
tent HIF-1α stabilizer DMOG, a specific inhibitor of
PHDs, to force HIF-1α stabilization in cells, and evaluated
their tumorigenic potential in soft agar. Interestingly,
DMOG-treated OS-93 CI-deficient cells displayed a sig-
nificantly increased colony-forming ability by about 50%
(P <0.05).
Discussion
In the present study, we demonstrate that functional
mitochondrial CI is required for the induction of the
Warburg phenotype, namely the metabolic reprogram-
ming of cancer cells towards glycolysis during tumor
progression in vivo. Our results strongly indicate that
the mechanism through which CI regulates the glycolytic
shift is mediated by HIF-1α stabilization, allowing tumor
cells to adapt to hypoxia and persist in proliferation.
In the last few years the Warburg effect has been
widely debated, in particular with respect to the role of
mitochondria in the regulation of cancer metabolism. In
fact, at least three of the four potential causes of the
Warburg effect revolve around metabolic processes that
converge directly or indirectly to mitochondria. In this
framework, it is interesting that two key enzymes of the
TCA cycle, namely FH and SDH (complex II of the re-
spiratory chain) are de facto tumor suppressor genes
whose loss-of-function mutations provide a permissive
environment for oncogenic hits to trigger transformation
[52]. The widely shown mechanism through which they
facilitate tumor growth/adaptation is the stabilization of
HIF-1α, the master mediator of progression towards ma-
lignancy, via the imbalance of TCA cycle metabolites α-KG and SA [53]. Our results show that, in contrast to
what occurs with FH and SDH, severe CI loss-of-function
mutations impinge on the cells ability to stabilize
HIF-1α despite hypoxia, via a shift in the α-KG/SA ratio
in favor of α-KG. We attempted to provide a functional
connection between these phenomena via the evaluation
of the NAD+/NADH ratio, which we confirmed to be
decreased in CI-deficient cells, likely due to a lower
NADH consumption in absence of the complex. It has
long been known that NADH accumulation contributes
to the allosteric inhibition of α-KG dehydrogenase, with
subsequent α-KG accumulation [54], which may lead
to HIF-1α destabilization and hence triggering of
pseudonormoxia.
These findings suggest that a novel two-way relation-
ship exists between HIF-1α and mitochondria, besides
the well-known negative regulation of pyruvate dehydro-
genase by pyruvate dehydrogenase kinase 1, which is a
known positive target of HIF-1α [12,13]. It has been pro-
posed that a slowdown in oxidative metabolism may
confer an advantage to tumor cells by decreasing their
oxygen requirements and by inducing anabolic reactions
[8,55]. Nevertheless, there is also evidence for a correl-
ation between CI inhibition and HIF-1α destabilization,
as shown using pharmacological treatment with respira-
tory chain inhibitors [56,57]. Moreover, several studies
have shown that loss of respiratory CIII may contribute
to ROS-mediated destabilization of HIF-1α [58,59], simi-
lar to the disassembling CI mutations that we have ex-
tensively reported [14,15]. We previously proved that
the homoplasmic m.3571insC/MT-ND1 mtDNA muta-
tion causes a complete loss of CI activity, hampering
tumor growth both in vitro and in vivo [15]. Such types
of homoplasmic disruptive mutations impinging on CI
function do occur in human cancers, where they are
generally associated to the oncocytic phenotype and to
an indolent, low aggressive behavior, and even to a
higher chromosomal stability [14,21,60-63].
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necessary for recovery of tumor growth, we complemented
the OS-93 cell line with the wild-type MT-ND1 using an
allotopic expression strategy. The xenografts subjected to
the next generation RNA-Seq technique showed significant
upregulation of ribosomal biogenesis and protein transla-
tion in tumors with a functional CI (Additional file 10:
Table S2), a profile previously defined as a molecular
marker of cancer phenotype. In fact, an augmented synthe-
sis of ribosomes, and consequently of proteins, can sustain
the high rate of proliferation required by cancer cells [64,65].
Moreover, a significant upregulation of HIF-1α-responsive
genes was detected in allotopic tumors, in particular those
involved in glycolytic metabolism. They were all found to
be overexpressed in cells with intact CI, defining a glyco-
lytic transcriptional profile typical of fast-growing tumors
[5,6,44,66]. The indication that such a HIF-1α-mediated
Warburg profile is essential to tumor progression was
provided by the rescue of anchorage-independent cell
growth upon forced stabilization of the transcription fac-
tor by DMOG.
Further studies in vivo are warranted to definitely
prove that pseudonormoxia is the main determinant of
the decreased tumorigenic potential of CI-deficient cells.
Nonetheless, our in vitro data support the hypothesis
that a strong metabolic impairment impacts on the HIF-
1α-dependent adaptive ability of cancer cells, likely via a
TCA imbalance. In fact, HIF-1α degradation is mediated
by the PHD enzymes, which hydroxylate the transcrip-
tion factor using α-KG in a reaction that in turn pro-
duces SA, an allosteric inhibitor of the PHDs [53].
Recovery of CI activity was shown here to restore a
physiological α-KG/SA ratio, indicating that TCA cycle
reactivation may be necessary to provide the metabolic
conditions for the induction of a hypoxic response with
a consequent HIF-1α stabilization (Figure 4E). Such a
condition may well depend on a re-balanced ratio of
NAD+/NADH, which followed CI recovery. In fact, such
a metabolite-sensing mechanism and allosteric enzyme
regulation may represent a quick route through which
cancer cells can respond to the selective pressure of the
ever-changing tumor microenvironment, as several stud-
ies underline [67]. A similar regulation may be crucial to
carry out the switch between glycolytic and oxidative
metabolism in specific phases of tumor progression, as
explained in a recently proposed wave-like model of
regulation of tumor metabolism [6].
Revitalization of mitochondrial function has been pro-
posed as one of the phases following hypoxic adaptation,
when nutrients and oxygen are again available to cancer
cells. In this context, inactivating CI mtDNA mutations,
such as m.3571insC/MT-ND1, may exhibit their effect
only at mitochondrial-dependent stages of tumor progres-
sion. These effects have been shown to vary, depending onmutant load and mutation type [21]. For instance, the
m.3571insC mutation investigated here has been shown to
exhibit anti-tumorigenic effects when present above the
83% threshold [15]. On the other hand, some missense CI
mtDNA mutations have been demonstrated to promote
tumor growth [18,19]. Overall, it is reasonable to suggest
that although a certain degree of mitochondrial dysfunction
can be advantageous when selective pressures operate, total
impairment of OXPHOS may not sustain tumor progres-
sion. It is therefore of paramount importance to note that
both the degree of heteroplasmy and the type of mutation
(missense vs truncating) must be carefully taken into ac-
count when considering the prognostic value of such
genetic markers, since they may determine a completely
opposite tumor fate, according to whether CI is functional
or not [15,20,21,68,69]. From our results, in fact, it has
emerged that intact CI is needed for adaptation to hypoxia,
which is in agreement with previous reports showing that
HIF-1α stabilization requires functional OXPHOS in condi-
tions of oxygen shortage [59,70].Conclusions
The role of CI in the induction of the Warburg pheno-
type and hypoxia response in cancer cells suggests that
it may no longer be considered an enzyme that merely
contributes to mitochondrial function, but that it may
be pivotal in determining the fate of cancer cells after
deregulation of their metabolic switch during tumor
progression. Therefore, CI, far from being considered a
tumor suppressor, ought more likely to be looked upon
as a lethality modifier of cancer cells when complete
loss-of-function mutations occur. Such concepts, epito-
mized by the definition of oncojanus mitochondrial mu-
tations [15], has potential applications in establishing
prognostic criteria, since genetic markers such as CI-
disruptive mutations may have a strong impact on the
successful metabolic adaptation of the neoplasia.Additional files
Additional file 1: Figure S1. DMOG effects validation. Western blot
analysis for hypoxia inducible factor-1α (HIF-1α) protein on cell lysates
upon treatment with 1 μM dimethyloxallylglycine (DMOG) indicate
presence of stabilized HIF-1α only in the treated cells despite normoxic
culture conditions. Tubulin was used as a loading control.
Additional file 2: Table S1. Raw sequencing data together with the
521 genes differentially expressed among the two groups of samples
(OST-93, OST-93ND1).
Additional file 3: Figure S2. FastQC analysis of fastq sequences from
the four data sets of samples. Panel A and B refer respectively to OST-93
samples and to OST-93ND1 samples. (a-c) the distribution of the average
quality scores per sequence within the set always ranges between 30 to
39 QS (quality score) values; (b-d) QS distribution per base position
across the maximum read length observed within the data set. In all four
samples the lower quartile associated to the 300th position of the read
(average read length for each sequences data set) is always above 20.
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Additional file 5: Figure S3. Generation of allotopic nND1. (A)
Elecropherogram showing m.3571insC in OS-93 cell line. (B) Amino acid
sequence of ND1. The sites of directed mutagenesis performed to
optimize codon usage for cytosolic translation of methionine (M) and
tryptophan (W) are underlined and indicated in bold. (C) Scheme of the
allotopic expression vector containing the nND1 transgene with the
30- and 50-UTR from the nuclear-encoded COX10 mitochondrial protein.
Antibiotic resistance genes, CMV promoter, SV40 and f1 origin of
replication are also indicated. (D) qRT-PCR showing mRNA expression of
the cytosolically expressed nND1 construct in OS-93 cells.
Additional file 6: Figure S4. Revertans exclusion. Denaturing high
performance liquid chromatography (DHPLC) analysis of the allotopically
complemented OS-93 cells. OS-93ND1#1 (cyan) has maintained the same
m.3571insC mutant load as the original OS-93 cell line (red), while OS-93
ND1#2 is a representative example of a revertant clone in which a higher
proportion of wild-type molecules is evident from the elevated elution
peak (pink).
Additional file 7: Figure S5. Cellular growth determination. Cellular
growth in DMEM-high glucose. Data represent mean ± standard error of
the mean (n = 3).
Additional file 8: Figure S6. Denaturing high performance liquid
chromatography (DHPLC) analysis of OS-93 and OS-93ND1 clones and
corresponding xenografts. Elution curves indicate maintenance of the
m.3571insC genotype (mutant loads >90%).
Additional file 9: Figure S7. Evaluation of reactive oxygen species
(ROS) levels. (A) Hydrogen peroxide levels were measured using 2 μM
H2DCFDA in the absence (basal) and presence of 1 uM antimycin A (AA)
for 1 h, as described in Additional file 4; Methods. Data (mean ± SD, n = 3;
*P <0.05) are expressed as ratio of fluorescence of H2DCFDA and calcein-
AM. (B) Superoxide production was determined using 5 μM MitoSOX-
Red, as described in Additional file 4; Methods. Images are representative
of three different experiments. Magnification 63×/1.4. Ten images were
acquired for each experiment.
Additional file 10: Table S2. Gene Ontology (GO) and Kyoto
Encyclopedia of Genes and Genomes (KEGG) categories enrichment
results: 34 GO categories and 8 KEGG categories were found significantly
enriched among all the 521 differentially expressed genes. GO
enrichments were also found by the GeneMania software among the
two sets of only overexpressed genes per sample (226 upregulated
genes within the OST-93 group and 296 upregulated genes within the
OST-93ND1 group).
Additional file 11: Figure S8. Correlation between RNA-Seq analysis
and qRT-PCR performed for 15/521 DE genes. Pearsons correlation
coefficient was calculated using log2fold values.
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